NCT04636983View on ClinicalTrials.gov

Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics of BV100 in Male Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

54

Participants

Timeline

Start Date

November 9, 2020

Primary Completion Date

December 12, 2021

Study Completion Date

January 20, 2022

Conditions

Healthy Subjects

Interventions

DRUG

BV100

Rifabutin IV

DRUG

Placebo

Saline

Trial Locations (1)

89231

Nuvisan GmbH, Neu-Ulm

Sponsors

Lead Sponsor

All Listed Sponsors

lead

BioVersys SAS

INDUSTRY

NCT04636983 - Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics of BV100 in Male Subjects | Biotech Hunter | Biotech Hunter